Propofol vs. Ketamin

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2012-001341-41-AT

Enrollment

Registered

2012-06-26

Start date

2012-11-13

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

major depression, bipolar disorder

Interventions

Trade Name: Propofol-Lipuro 10 mg/ml-Emulsion zur Injektion oder Infusion Product Name: Propofol-Lipuro 10 mg/ml-Emulsion zur Injektion oder Infusion Product Code: SUB10116MIG Pharmaceutical Form: Emu

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patient with depression, older than 18 years Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 40 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Encephalitis disseminata fresh myocardial infarct or stroke pacemaker cerebral lesion expansion psychiatric comorbidity of F1 in ICD-10

Design outcomes

Primary

Measure	Time frame
Main Objective: better therapeutic effect of ketamin in the treatment of ECT ;Secondary Objective: n.a.;Primary end point(s): good therapeutic effect of ketamin in the treatment of ect;Timepoint(s) of evaluation of this end point: 4 weeks	—

Secondary

Measure	Time frame
Secondary end point(s): n.a.;Timepoint(s) of evaluation of this end point: 2 years	—

Countries

Austria

Contacts

Public ContactUKPP I

Universitätsklinik für Psychiatrie und Psychotherapie I

ev.pichler@salk.at0043662448356746

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026